Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's EV-to-EBIT for today is
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Enterprise Value is E£12,430 Mil.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£980 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's EV-to-EBITDA for today is:
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Enterprise Value is E£12,430 Mil.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£1,073 Mil.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Enterprise Value is E£12,430 Mil.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£4,297 Mil.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Enterprise Value is E£12,430 Mil.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£-68 Mil.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Enterprise Value is E£12,430 Mil.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£-821 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Enterprise Value Related Terms
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Enterprise Value Chart
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Enterprise Value vs Drug Manufacturers Industry
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of E£12,430 Mil mean?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) has a Enterprise Value of E£12,430 Mil as of Jul. 06, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Enterprise Value too high?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' current Enterprise Value is E£12,430 Mil. Overall, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Enterprise Value compare to ZTS and UTHR?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Enterprise Value of E£12,430 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Enterprise Value is E£12,430 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock overvalued right now?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) is currently considered Modestly Overvalued. The stock's GF Value™ is E£4.08, compared to a current price of E£5.10 — trading 25% above its estimated fair value. The current Enterprise Value is E£12,430 Mil. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA), the current Enterprise Value is E£12,430 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock appears to be overvalued.
The current stock price of E£5.10 is trading 25% above its estimated GF Value™ of E£4.08.
GuruFocus considers Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents to be Modestly Overvalued.
Key valuation signals for CAI:RMDA:
Enterprise Value: E£12,430 Mil
GF Value™: E£4.08 vs. price of E£5.10 (25% above fair value)
No single metric tells the full story. See the CAI:RMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Business Description
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
84GF Score
Get the complete analysis for CAI:RMDA
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:RMDA has been successfully added to your 
